Do Not Pass Go: Board Dismisses Claim on Jurisdictional Grounds
Client Alert | 1 min read | 10.20.17
In Elham Ahmadi Construction Company (ASBCA No. 61031), the Board determined it lacked jurisdiction to consider a contractor’s appeal arising from a termination for default and the contractor’s related claim to recover payment for work that was performed and accepted by the Government prior to the termination. First, the Board held that while “a termination for default is both a government claim and contracting officer’s final decision that can be directly appealed to the Board,” a contractor must appeal such termination within the statutorily-mandated 90 days. Because the contractor did not contest the termination until six years after the termination, the Board concluded it lacked jurisdiction to consider the termination’s propriety. Second, the Board concluded that the contractor’s claim – which requested “about $71500 Dollars” – did not constitute a claim because it lacked the required sum certain. The Board explained that qualifiers such as “about” or “at least” make a sum uncertain and deprive the Board of jurisdiction, a reminder to contractors to observe the jurisdictional prerequisites in the Contract Disputes Act and the FAR, or risk forfeiting otherwise viable claims.
Contacts
Insights
Client Alert | 9 min read | 10.21.26
The life sciences sector is uniquely vulnerable to the inherent risks of AI-generated evidence in drug development and discovery. This client alert focuses on five core challenges: hallucinations, skewed predictions from unrepresentative training data, the opacity of AI reasoning, input sensitivity that undermines reproducibility, and adversarial manipulation of training data. To address these risks, companies should use experimental validation and human oversight as the common legal and regulatory safety net. This entails among other measures auditing AI outputs, characterizing training data, and structural oversight. Companies also should prepare for evolving frameworks and guidance from the U.S. Food and Drug Administration (FDA) and the European Union (EU) that address use of AI in drug discovery and development .
Client Alert | 2 min read | 10.21.26
Client Alert | 3 min read | 10.21.26
Private Investigations Act Series: Temporal, material and territorial scope
Client Alert | 7 min read | 10.21.26




